PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 482
- Registration Number
- NCT00373113
- Locations
- π¬π§
Pfizer Investigational Site, Somerset, United Kingdom
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Phase 3
Terminated
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT00372567
- Locations
- π¬π§
Pfizer Investigational Site, Manchester, United Kingdom
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00372775
- Locations
- πͺπΈ
Pfizer Investigational Site, Valencia, Spain
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00372996
- Locations
- π¦π·
Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina
π§πͺUZ Gasthuisberg, Medische Oncologie, Leuven, Belgium
π¦π·Centro Oncologico Rosario, Rosario, Santa Fe, Argentina
An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 334
- Registration Number
- NCT00371813
- Locations
- πΉπ
Pfizer Investigational Site, Chiang Mai, Thailand
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2007-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 345
- Registration Number
- NCT00370565
- Locations
- π¨π¦
Pfizer Investigational Site, Laval, Quebec, Canada
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
Phase 2
Terminated
- Conditions
- Obesity
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00367783
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 397
- Registration Number
- NCT00367653
- Locations
- πΏπ²
Pfizer Investigational Site, Ndola, Zambia
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00367445
- Locations
- πΊπΈ
Pfizer Investigational Site, Chula Vista, California, United States
Zmax Compared to Augmentin in Sinusitis
Phase 4
Completed
- Conditions
- Sinusitis
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 762
- Registration Number
- NCT00367120
Β© Copyright 2025. All Rights Reserved by MedPath